Skip to main content
SpringerLink
Log in

Atazanavir-based dual therapy decreases costs in HIV patients

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2016 euros

Reference

  • Restelli U, et al. Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial. ClinicoEconomics and Outcomes Research 2017: 569-571, No. 9, 27 Sep 2017. Available from: URL: https://doi.org/10.2147/CEOR.S143377

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atazanavir-based dual therapy decreases costs in HIV patients. PharmacoEcon Outcomes News 789, 11 (2017). https://doi.org/10.1007/s40274-017-4418-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4418-5

Search

Navigation